Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

NCT01164995 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: MK-1775 and carboplatin

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]